Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The Company, through its Interpace Diagnostics, provides clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, which is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, which is a molecular version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT, which is for the diagnosis of thyroid cancer from thyroid nodules utilizing a sequencing assay; ThyraMIR v2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer, and RespriDX, which differentiates lung cancer of primary versus metastatic origin.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)